Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Sangro

Showing results (71-80 of 76) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 76 results.
Molecular Pharmaceutics|April 25, 2012
No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumorsP Martinez-Becerra, J Vaquero, M R Romero, et al.
Cardiovascular and Interventional Radiology|January 14, 2025
Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational StudyM Ronot, R Loffroy, D Arnold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 27, 2023
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040A B El-Khoueiry, J Trojan, T Meyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 6, 2024
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040I Melero, T Yau, Y-K Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaB Sangro, S L Chan, R K Kelley, et al.
ESMO Open|June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Pageof 8

Showing results (71-80 of 76) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 76 results.
Molecular Pharmaceutics|April 25, 2012
No correlation between the expression of FXR and genes involved in multidrug resistance phenotype of primary liver tumorsP Martinez-Becerra, J Vaquero, M R Romero, et al.
Cardiovascular and Interventional Radiology|January 14, 2025
Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational StudyM Ronot, R Loffroy, D Arnold, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 27, 2023
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040A B El-Khoueiry, J Trojan, T Meyer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 6, 2024
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040I Melero, T Yau, Y-K Kang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 21, 2024
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinomaB Sangro, S L Chan, R K Kelley, et al.
ESMO Open|June 1, 2023
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022M Ducreux, G K Abou-Alfa, T Bekaii-Saab, et al.
Pageof 8